Protect them as if they were your own...
Follow the Advisory Committee on Immunization Practices’ (ACIP) recommendations for meningococcal vaccination1
- Routine meningococcal vaccination for all adolescents 11-18 years of age1
- The pre-adolescent visit at 11-12 years of age is the best time to vaccinate1
- Previously unvaccinated 11-18 year olds should be immunized at the earliest possible health-care visit1
Take advantage of every opportunity to vaccinate
- Give all recommended vaccines at a single visit1,2
- Immunize even during sick visits for minor illnesses
- Implement standing orders
Menactra vaccine is indicated for active immunization against invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135 in persons 2 through 55 years of age. Menactra vaccine will not stimulate protection against infection caused by N meningitidis other than serogroups A, C, Y, and W-135.
The most common local and systemic adverse reactions to Menactra vaccine include injection site pain, redness, and induration; headache, fatigue, and malaise. Other adverse reactions may occur. Menactra vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine or to latex, which is used in the vial stopper. Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of Menactra vaccine. Persons previously diagnosed with GBS should not receive Menactra vaccine. Vaccination with Menactra vaccine may not protect all individuals.
Before administering Menactra vaccine, please see full Prescribing Information.
References: 1. Centers for Disease Control and Prevention (CDC). Notice to readers: Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR. 2007;56(31):794-795. 2. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR.